As guidelines to treat the risk factors of cardiovascular disease continue to evolve, Michael Weber, MD, explains how new editions of lipid, diabetes, and hypertension guidelines continue to improve patient care.
Dr Weber explains that we should not expect to see major changes as new treatment guidelines continue to develop, however, since last published several years ago, these guidelines are helpful because they are based on evidence, which is the basis to a good set of guidelines.
Dr Weber is confident in the decisions highlighted inside new guidelines by organized bodies such as the American Diabetes Association, National Kidney Foundation, and Joint National Committee because he feels that these bodies are putting a lot of effort into creating them.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
Moving Evidence From Research to Practice: Q&A With Ken Cohen, MD
June 23rd 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.
Read More